Biocon to fully integrate Biocon Biologics, boost capital by INR 6,950 crore

On December 6, 2025, Biocon Limited announced board approval to fully integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary. This move is set to streamline its corporate structure and enhance financial metrics. The acquisition involves a share swap for certain minority shareholders and a cash consideration of $400 million to Mylan Inc. (Viatris) for 14,36,69,382 BBL shares. The total consideration for BBL's acquisition is $815 million, valuing BBL at $5.5 billion.

The company plans to issue 17,12,79,553 equity shares on a preferential basis, aggregating up to INR 6,950 crore, at INR 405.78 per share, to the selling shareholders as part of the transaction. Additionally, Biocon will raise up to INR 4,500 crore through various instruments, including a QIP, and issue Commercial Papers worth up to INR 1,800 crore for interim funding. An Extra-Ordinary General Meeting (EGM) is scheduled for December 31, 2025, to seek shareholder approval for these proposals.

An analyst call and presentation are scheduled for Monday, December 8, 2025, at 08:00 hrs IST to discuss the integration, which is expected to be completed by Q4 FY2026.